A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Phase 3
110
about 7.1 years
4–17
11 sites in CA, FL, IL +4
What this study is about
Researchers are testing how well zasocitinib works, how safe it is, and how children and teenagers with plaque psoriasis respond to the treatment. The trial will last up to 4 years and 2 months for participants who are enrolled. Participants will visit their trial site multiple times during it.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Zasocitinib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
kinase inhibitor
Primary: Part B: Maximum Observed Plasma Concentration (Cmax) of Zasocitinib, Part B: Time to Maximum Concentration (Tmax) of Zasocitinib
Secondary: Part A (Cohort 1): Change From Baseline in Itch NRS at Week 16, Part A (Cohort 1): Change From Baseline in Itch NRS for Participants in Cohort 1 During Open-Label Period, Part A (Cohort 1): Percent Change From Baseline in Itch NRS at Week 16, Part A (Cohort 1): Percent Change From Baseline in Itch NRS for Participants in Cohort 1 During Open-Label Period, Part A (Cohort 1): Percentage of Participants in Cohort 1 with a Baseline Itch Numerical Rating Scale (NRS) Score >=4 who Achieve a >= 4-Point Improvement in Itch NRS Score at Week 16, Part A (Cohort 1): Percentage of Participants with a Baseline Itch Numerical Rating Scale (NRS) Score >=4 who Achieve a >= 4-Point Improvement in Itch NRS Score During Open-Label Period, Part A: Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16, Part A: Change From Baseline in CDLQI at Week 16
Dermatology